SULT1E1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5708656	0.46	2/20
SCHEMBL29955707	0.42	2/20
SCHEMBL11541084	0.38	2/20
SCHEMBL28295389	0.38	2/20
SCHEMBL8171800	0.37	2/20
SCHEMBL29956932	0.36	2/20
SCHEMBL981569	0.35	2/20
SCHEMBL7026584	0.34	2/20
SCHEMBL28346097	0.34	2/20
SCHEMBL13446722	1.00	1/20
SCHEMBL4451477	0.59	1/20
SCHEMBL13446724	0.59	1/20
SCHEMBL8667490	0.58	1/20
SCHEMBL13446723	0.54	1/20
SCHEMBL13856769	0.52	1/20
SCHEMBL13446725	0.52	1/20
SCHEMBL13446727	0.52	1/20
SCHEMBL29768747	0.52	1/20
SCHEMBL14880592	0.51	1/20
SCHEMBL20640640	0.47	1/20

Clinical trials — most relevant to SULT1E1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients	PHASE3	COMPLETED
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	PHASE3	UNKNOWN
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer	PHASE2	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy	PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma	PHASE1/PHASE2	RECRUITING
Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults	PHASE1	COMPLETED
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers	PHASE1	COMPLETED
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study	PHASE1	COMPLETED
Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet	EARLY_PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
APAP Hepatotoxicity After Therapeutic Doses	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva	nan	COMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer	nan	COMPLETED
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles	nan	COMPLETED
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SULT1E1 binder may also engage these)

Protein	Name	Similarity
P19217	—	1.000	P19217 →
O43704	—	1.000	O43704 →
Q80VR3	—	1.000	Q80VR3 →
Q3UZZ6	—	1.000	Q3UZZ6 →
G3V9R3	—	1.000	G3V9R3 →
Q9QWG7	—	1.000	Q9QWG7 →
Q3T0Y3	—	0.999	Q3T0Y3 →
P49887	—	0.998	P49887 →
Q9WUW9	—	0.998	Q9WUW9 →
Q95JD5	—	0.998	Q95JD5 →
Q9D939	—	0.997	Q9D939 →
O00338	—	0.996	O00338 →
P52847	—	0.996	P52847 →
P52841	—	0.996	P52841 →
P49891	—	0.996	P49891 →
Q6IMI6	—	0.995	Q6IMI6 →
A0A2K5X3B6	—	0.995	A0A2K5X3B6 →
O75897	—	0.995	O75897 →
P50237	—	0.994	P50237 →
P52840	—	0.994	P52840 →
P52844	—	0.993	P52844 →
B2RVI8	—	0.992	B2RVI8 →
Q29476	—	0.991	Q29476 →
P17988	—	0.991	P17988 →
P0CC03	—	0.991	P0CC03 →
Q6PH37	—	0.991	Q6PH37 →
Q6IMI4	—	0.990	Q6IMI4 →
Q9WUW8	—	0.990	Q9WUW8 →
O46503	—	0.990	O46503 →
Q8BGL3	—	0.989	Q8BGL3 →